Cogent Biosciences (COGT) Is Up 144.5% After Bezuclastinib Phase 3 Win and $500M Capital Raise Has The Bull Case Changed? [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
imatinib-resistant or intolerant gastrointestinal stromal tumors (GIST), showing the combination nearly doubled median progression-free survival compared to standard therapy. This clinical milestone prompted the company to raise US$300 million in follow-on equity and US$200 million through convertible senior notes to accelerate bezuclastinib's regulatory and commercial pathway. We'll consider how these successful late-stage trial results influence Cogent Biosciences' investment narrative and highlight potential near-term regulatory milestones. Uncover the next big thing with financially sound penny stocks that balance risk and reward What Is Cogent Biosciences' Investment Narrative? To believe in Cogent Biosciences as a shareholder, you need conviction in its ability to turn a high-profile clinical win into regulatory and commercial success, all while managing operational losses and dilution risk. The recent Phase 3 PEAK trial results for bezuclastinib, which cut the risk of
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences (NASDAQ:COGT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces Participation in the Jefferies Global Healthcare ConferenceGlobeNewswire
- Cogent Biosciences (NASDAQ:COGT) had its price target raised by analysts at HC Wainwright from $21.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031GlobeNewswire
COGT
Sec Filings
- 11/18/25 - Form 8-K
- 11/17/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- COGT's page on the SEC website